We’ve recently updated our valuation analysis.

ObsEva Valuation

Is OBSV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

[object Object] Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OBSV?

Other financial metrics that can be useful for relative valuation.

OBSV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.9x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OBSV's PS Ratio compare to its peers?

The above table shows the PS ratio for OBSV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.8x
BIOC Biocept
0.3x21.0%US$13.0m
CNTG Centogene
0.1x-56.6%US$21.5m
APVO Aptevo Therapeutics
2.3x-130.7%US$15.8m
SBFM Sunshine Biopharma
36.3xn/aUS$17.8m
OBSV ObsEva
5x31.9%US$18.6m

Price-To-Sales vs Peers: OBSV is good value based on its Price-To-Sales Ratio (5x) compared to the peer average (9.8x).


Price to Earnings Ratio vs Industry

How does OBSV's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Sales vs Industry: OBSV is good value based on its Price-To-Sales Ratio (5x) compared to the US Biotechs industry average (12x)


Price to Sales Ratio vs Fair Ratio

What is OBSV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OBSV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5x
Fair PS Ratio5.2x

Price-To-Sales vs Fair Ratio: OBSV is good value based on its Price-To-Sales Ratio (5x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).


Share Price vs Fair Value

What is the Fair Price of OBSV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OBSV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OBSV's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OBSV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.18
US$4.67
+2,436.2%
111.1%US$12.00US$1.00n/a3
Nov ’23US$0.18
US$4.67
+2,508.5%
111.1%US$12.00US$1.00n/a3
Oct ’23US$0.14
US$4.67
+3,184.1%
111.1%US$12.00US$1.00n/a3
Sep ’23US$0.18
US$4.67
+2,527.6%
111.1%US$12.00US$1.00n/a3
Aug ’23US$0.24
US$6.25
+2,504.2%
84.2%US$12.00US$1.00n/a4
Jul ’23US$1.76
US$10.25
+482.4%
24.3%US$12.00US$6.00n/a4
Jun ’23US$1.84
US$11.67
+534.1%
4.0%US$12.00US$11.00n/a3
May ’23US$1.50
US$11.67
+677.8%
4.0%US$12.00US$11.00n/a3
Apr ’23US$1.52
US$11.50
+656.6%
4.3%US$12.00US$11.00n/a2
Mar ’23US$1.33
US$15.00
+1,027.8%
0%US$15.00US$15.00n/a1
Feb ’23US$1.53
US$15.00
+880.4%
0%US$15.00US$15.00n/a1
Jan ’23US$1.99
US$15.00
+653.8%
0%US$15.00US$15.00n/a1
Dec ’22US$2.15
US$15.00
+597.7%
0%US$15.00US$15.00US$0.211
Nov ’22US$2.56
US$17.00
+564.1%
0%US$17.00US$17.00US$0.181
Oct ’22US$3.10
US$18.81
+506.8%
9.6%US$20.62US$17.00US$0.142
Sep ’22US$3.04
US$19.00
+525.0%
10.5%US$21.00US$17.00US$0.182
Aug ’22US$2.52
US$19.00
+654.0%
10.5%US$21.00US$17.00US$0.242
Jul ’22US$2.99
US$20.50
+585.6%
17.1%US$24.00US$17.00US$1.762
Jun ’22US$2.89
US$20.50
+609.3%
17.1%US$24.00US$17.00US$1.842
May ’22US$3.13
US$22.50
+618.8%
24.4%US$28.00US$17.00US$1.502
Apr ’22US$3.35
US$13.75
+310.4%
69.8%US$28.00US$4.00US$1.524
Mar ’22US$3.85
US$12.00
+211.7%
77.3%US$28.00US$4.00US$1.335
Feb ’22US$3.83
US$12.00
+213.3%
77.3%US$28.00US$4.00US$1.535
Jan ’22US$2.08
US$13.40
+544.2%
75.5%US$28.00US$4.00US$1.995
Dec ’21US$2.16
US$13.40
+520.4%
75.5%US$28.00US$4.00US$2.155

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies